Does the media refer more to HROW or AMRX?

In the previous week, Amneal Pharmaceuticals had 20 more articles in the media than Harrow. MarketBeat recorded 21 mentions for Amneal Pharmaceuticals and 1 mentions for Harrow. Harrow's average media sentiment score of 1.17 beat Amneal Pharmaceuticals' score of 0.88 indicating that Harrow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 9 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, HROW or SRRK?

Harrow has higher revenue and earnings than Scholar Rock. Harrow is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Harrow $268.68M 5.38 -$5.14M -$0.41 N/A Scholar Rock N/A N/A -$377.94M -$3.59 N/A

Is HROW or SRRK more profitable?

Scholar Rock has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Harrow -5.57% 19.59% 2.26% Scholar Rock N/A -163.52% -96.67%

Does the media prefer HROW or SRRK?

In the previous week, Scholar Rock had 7 more articles in the media than Harrow. MarketBeat recorded 8 mentions for Scholar Rock and 1 mentions for Harrow. Harrow's average media sentiment score of 1.17 beat Scholar Rock's score of 0.98 indicating that Harrow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HROW or DNTH?

In the previous week, Dianthus Therapeutics had 9 more articles in the media than Harrow. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 1 mentions for Harrow. Dianthus Therapeutics' average media sentiment score of 1.39 beat Harrow's score of 1.17 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is HROW or TWST more profitable?

Harrow has a net margin of -5.57% compared to Twist Bioscience's net margin of -19.85%. Harrow's return on equity of 19.59% beat Twist Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Harrow -5.57% 19.59% 2.26% Twist Bioscience -19.85% -26.73% -19.15%

Does the media refer more to HROW or TWST?

In the previous week, Twist Bioscience had 7 more articles in the media than Harrow. MarketBeat recorded 8 mentions for Twist Bioscience and 1 mentions for Harrow. Twist Bioscience's average media sentiment score of 1.24 beat Harrow's score of 1.17 indicating that Twist Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor ORKA or HROW?

In the previous week, Oruka Therapeutics had 3 more articles in the media than Harrow. MarketBeat recorded 4 mentions for Oruka Therapeutics and 1 mentions for Harrow. Oruka Therapeutics' average media sentiment score of 1.25 beat Harrow's score of 1.17 indicating that Oruka Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harrow 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Harrow (HROW) Competitors

$38.77 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$38.09 -0.68 (-1.75%)

As of 07/31/2026 07:50 PM Eastern

Compare

HROW vs. AMRX, SRRK, DNTH, TWST, and ORKA

Should you buy Harrow stock or one of its competitors? MarketBeat compares Harrow with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Harrow include Amneal Pharmaceuticals (AMRX), Scholar Rock (SRRK), Dianthus Therapeutics (DNTH), Twist Bioscience (TWST), and Oruka Therapeutics (ORKA).

How does Harrow compare to Amneal Pharmaceuticals?

Harrow (NASDAQ:HROW) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

Amneal Pharmaceuticals has a net margin of 5.05% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Amneal Pharmaceuticals has higher revenue and earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$268.68M	5.38	-$5.14M	-$0.41	N/A
Amneal Pharmaceuticals	$3.02B	1.94	$72.06M	$0.49	37.39

72.8% of Harrow shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 12.8% of Harrow shares are held by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Harrow presently has a consensus price target of $69.43, indicating a potential upside of 79.08%. Amneal Pharmaceuticals has a consensus price target of $17.33, indicating a potential downside of 5.39%. Given Harrow's higher probable upside, equities research analysts clearly believe Harrow is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

In the previous week, Amneal Pharmaceuticals had 20 more articles in the media than Harrow. MarketBeat recorded 21 mentions for Amneal Pharmaceuticals and 1 mentions for Harrow. Harrow's average media sentiment score of 1.17 beat Amneal Pharmaceuticals' score of 0.88 indicating that Harrow is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	9 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Harrow has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

Summary

Amneal Pharmaceuticals beats Harrow on 10 of the 16 factors compared between the two stocks.

How does Harrow compare to Scholar Rock?

Harrow (NASDAQ:HROW) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

In the previous week, Scholar Rock had 7 more articles in the media than Harrow. MarketBeat recorded 8 mentions for Scholar Rock and 1 mentions for Harrow. Harrow's average media sentiment score of 1.17 beat Scholar Rock's score of 0.98 indicating that Harrow is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

72.8% of Harrow shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 12.8% of Harrow shares are held by insiders. Comparatively, 10.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Harrow has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Harrow presently has a consensus price target of $69.43, indicating a potential upside of 79.08%. Scholar Rock has a consensus price target of $56.21, indicating a potential upside of 18.87%. Given Harrow's higher probable upside, research analysts clearly believe Harrow is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

Scholar Rock has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
Scholar Rock	N/A	-163.52%	-96.67%

Harrow has higher revenue and earnings than Scholar Rock. Harrow is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$268.68M	5.38	-$5.14M	-$0.41	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

Summary

Harrow and Scholar Rock tied by winning 8 of the 16 factors compared between the two stocks.

How does Harrow compare to Dianthus Therapeutics?

Harrow (NASDAQ:HROW) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Harrow has a net margin of -5.57% compared to Dianthus Therapeutics' net margin of -12,998.50%. Harrow's return on equity of 19.59% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%

In the previous week, Dianthus Therapeutics had 9 more articles in the media than Harrow. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 1 mentions for Harrow. Dianthus Therapeutics' average media sentiment score of 1.39 beat Harrow's score of 1.17 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dianthus Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harrow has higher revenue and earnings than Dianthus Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$268.68M	5.38	-$5.14M	-$0.41	N/A
Dianthus Therapeutics	$1.34M	4,374.92	-$162.34M	-$4.13	N/A

Harrow has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

72.8% of Harrow shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 12.8% of Harrow shares are owned by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Harrow presently has a consensus price target of $69.43, suggesting a potential upside of 79.08%. Dianthus Therapeutics has a consensus price target of $117.82, suggesting a potential upside of 10.19%. Given Harrow's higher possible upside, analysts plainly believe Harrow is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Harrow beats Dianthus Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Harrow compare to Twist Bioscience?

Harrow (NASDAQ:HROW) and Twist Bioscience (NASDAQ:TWST) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Harrow presently has a consensus price target of $69.43, suggesting a potential upside of 79.08%. Twist Bioscience has a consensus price target of $90.30, suggesting a potential downside of 1.37%. Given Harrow's higher possible upside, equities analysts plainly believe Harrow is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Harrow has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.11, suggesting that its stock price is 111% more volatile than the broader market.

Harrow has higher earnings, but lower revenue than Twist Bioscience. Harrow is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$268.68M	5.38	-$5.14M	-$0.41	N/A
Twist Bioscience	$409.48M	13.92	-$77.67M	-$1.33	N/A

Harrow has a net margin of -5.57% compared to Twist Bioscience's net margin of -19.85%. Harrow's return on equity of 19.59% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
Twist Bioscience	-19.85%	-26.73%	-19.15%

72.8% of Harrow shares are owned by institutional investors. 12.8% of Harrow shares are owned by company insiders. Comparatively, 3.1% of Twist Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Twist Bioscience had 7 more articles in the media than Harrow. MarketBeat recorded 8 mentions for Twist Bioscience and 1 mentions for Harrow. Twist Bioscience's average media sentiment score of 1.24 beat Harrow's score of 1.17 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Harrow beats Twist Bioscience on 8 of the 15 factors compared between the two stocks.

How does Harrow compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Harrow (NASDAQ:HROW) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Oruka Therapeutics presently has a consensus target price of $134.30, indicating a potential upside of 39.16%. Harrow has a consensus target price of $69.43, indicating a potential upside of 79.08%. Given Harrow's higher possible upside, analysts clearly believe Harrow is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Oruka Therapeutics has a beta of -0.35, suggesting that its share price is 135% less volatile than the broader market. Comparatively, Harrow has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

Harrow has higher revenue and earnings than Oruka Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A
Harrow	$268.68M	5.38	-$5.14M	-$0.41	N/A

Oruka Therapeutics has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.16%	-25.00%
Harrow	-5.57%	19.59%	2.26%

In the previous week, Oruka Therapeutics had 3 more articles in the media than Harrow. MarketBeat recorded 4 mentions for Oruka Therapeutics and 1 mentions for Harrow. Oruka Therapeutics' average media sentiment score of 1.25 beat Harrow's score of 1.17 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harrow	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 12.8% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Harrow beats Oruka Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Harrow News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HROW vs. The Competition

Export

Metric	Harrow	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.45B	$11.71B	$6.85B	$12.42B
Dividend Yield	N/A	2.72%	2.59%	10.03%
P/E Ratio	-94.56	799.05	282.30	24.66
Price / Sales	5.38	748.51	563.12	75.93
Price / Cash	44.86	14.82	28.60	46.71
Price / Book	27.50	10.28	10.96	6.07
Net Income	-$5.14M	$2.82B	$3.49B	$347.99M
7 Day Performance	3.50%	-0.16%	-0.64%	-0.44%
1 Month Performance	-9.29%	-4.00%	-5.23%	-4.81%
1 Year Performance	24.14%	156.08%	61.97%	18.61%

Harrow Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HROW Harrow	4.1591 of 5 stars	$38.77 flat	$69.43 +79.1%	+24.1%	$1.45B	$268.68M	N/A	180	Positive News Upcoming Earnings
AMRX Amneal Pharmaceuticals	2.8875 of 5 stars	$18.09 +0.9%	$16.60 -8.2%	+134.0%	$5.72B	$3.02B	47.61	8,500	Trending News Analyst Forecast
SRRK Scholar Rock	3.1437 of 5 stars	$48.93 +2.6%	$56.00 +14.4%	+30.1%	$5.71B	N/A	N/A	140	Upcoming Earnings Gap Up
DNTH Dianthus Therapeutics	2.1214 of 5 stars	$104.49 +0.6%	$117.82 +12.8%	+419.3%	$5.68B	$2.04M	N/A	80	Positive News Upcoming Earnings Gap Up
TWST Twist Bioscience	1.427 of 5 stars	$86.54 -4.1%	$90.30 +4.3%	+171.8%	$5.62B	$409.48M	N/A	990	News Coverage Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HROW) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harrow (HROW) Competitors

HROW vs. AMRX, SRRK, DNTH, TWST, and ORKA

How does Harrow compare to Amneal Pharmaceuticals?

Summary

How does Harrow compare to Scholar Rock?

Summary

How does Harrow compare to Dianthus Therapeutics?

Summary

How does Harrow compare to Twist Bioscience?

Summary

How does Harrow compare to Oruka Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HROW vs. The Competition

Harrow Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harrow (HROW) Competitors

HROW vs. AMRX, SRRK, DNTH, TWST, and ORKA

How does Harrow compare to Amneal Pharmaceuticals?

Is HROW or AMRX more profitable?

Which has higher valuation and earnings, HROW or AMRX?

Do insiders and institutionals hold more shares of HROW or AMRX?

Do analysts rate HROW or AMRX?

Does the media refer more to HROW or AMRX?

Which has more risk and volatility, HROW or AMRX?

Summary

How does Harrow compare to Scholar Rock?

Does the media prefer HROW or SRRK?

Do institutionals and insiders hold more shares of HROW or SRRK?

Which has more volatility & risk, HROW or SRRK?

Do analysts rate HROW or SRRK?

Is HROW or SRRK more profitable?

Which has better earnings and valuation, HROW or SRRK?

Summary

How does Harrow compare to Dianthus Therapeutics?

Is HROW or DNTH more profitable?

Does the media refer more to HROW or DNTH?

Which has higher earnings & valuation, HROW or DNTH?

Which has more risk and volatility, HROW or DNTH?

Do insiders and institutionals hold more shares of HROW or DNTH?

Do analysts recommend HROW or DNTH?

Summary

How does Harrow compare to Twist Bioscience?

Do analysts recommend HROW or TWST?

Which has more risk & volatility, HROW or TWST?

Which has better valuation and earnings, HROW or TWST?

Is HROW or TWST more profitable?

Do institutionals and insiders hold more shares of HROW or TWST?

Does the media refer more to HROW or TWST?

Summary

How does Harrow compare to Oruka Therapeutics?

Do analysts rate ORKA or HROW?

Which has more risk and volatility, ORKA or HROW?

Which has better earnings & valuation, ORKA or HROW?

Is ORKA or HROW more profitable?

Does the media favor ORKA or HROW?

Do institutionals and insiders hold more shares of ORKA or HROW?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HROW vs. The Competition

Harrow Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools